Integrating Targeted Molecular Therapy for Renal Cell Carcinoma.

The article discusses issues related to the emergence of targeted molecular therapies as mainstays of treating advanced renal cell carcinoma (RCC). According to the article, the discovery of specific genes, gene products and aberrant molecular pathways associated with RCC has fueled the development of targeted therapies and clinical trials examining their efficacy. The article also discusses the rationale and evidence for targeted therapy strategies.